A Pilot Project to Assess the Pharmacoeconomic Feasibility ofSubcutaneous Immunoglobulin for Neuromuscular Diseases
For the management of neuromuscular disorders (NMD), subcutaneous immunoglobulin (SCIg) administration has become an alternate option, being a home-based alternative to conventional intravenous immunoglobulin (IVIg), with a comparable efficacy, minimum adverse effects and significant improvement to the quality of life. With the increased cost of healthcare management, it has become more challenging for clinicians and other healthcare decision makers to come up with a better alternative while considering economics factors, though as a secondary. There is not much knowledge about the cost of the management of NMDs with the alternative SCIg therapy along the side of IVIg. This study is aimed to assess the direct as well as indirect costs of the management of NMDs with SCIg while identifying healthcare resources utilization and considering the quality of
life as a major factor.